Mersana Therapeutics (MRSN) Misses Q4 EPS by 28c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to Mersana Therapeutics (MRSN) Misses Q4 EPS by 28c, Revenues Miss

 Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates

March 8, 2019 6:00 AM EST

Company Plans to Report XMT-1536 Dose Escalation Data in the Second Quarter of 2019

Ended 2018 with $70 Million in Cash

Further Strengthened Balance Sheet with Gross Proceeds of $98 Million from Equity Financing; Expected to Fund the Company Through Important Clinical Milestones

CAMBRIDGE, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial... More